Pharmacological and clinical studies of ephedrine and other thermogenic agonists

Obes Res. 1995 Nov;3 Suppl 4:537S-540S. doi: 10.1002/j.1550-8528.1995.tb00224.x.

Abstract

When given as a supplement to an energy restricted diet the sympathomimetic agent ephedrine, in combination with methylxanthines such as caffeine, improves fat loss by dual actions: a central suppression of appetite and peripheral stimulation of energy expenditure covered by fat oxidation. Mean weight loss was found to be 16.6 kg after 6 months when E+C was given as an adjuvant to an efficient hypoenergetic diet, which was 3.4 kg higher than in the placebo group. An additional 24 weeks treatment with E+C prevented relapse. In the first weeks of treatment E+C offset the hypotensive effect of energy restriction and weight loss, but the effect was transient, and after 8 weeks blood pressures were indistinguishable from those of the placebo group. E+C has no adverse effect on glucose and lipid metabolism, but has been shown to prevent the decline in HDL-cholesterol caused by weight loss. In a comparative trial the weight loss produced by E+C was similar to that of dexfenfluramine. More research on sympathomimetics and methylxanthines should be carried out to identify combinations with improved efficiency and safety. Moreover, more long-term trials and studies in males are required.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Review

MeSH terms

  • Appetite Depressants / therapeutic use
  • Body Temperature Regulation / drug effects*
  • Caffeine / therapeutic use
  • Ephedrine / pharmacology*
  • Ephedrine / therapeutic use*
  • Humans
  • Obesity / drug therapy*
  • Sympathomimetics / therapeutic use

Substances

  • Appetite Depressants
  • Sympathomimetics
  • Caffeine
  • Ephedrine